Sellas Life Sciences closes $172.5 million stock offering
SELLAS Life Sciences Group, Inc. successfully closed its underwritten public offering of 13,269,231 shares of common stock at $13.00 per share, raising a total of $172.5 million in gross proceeds. The biopharmaceutical company, which specializes in developing cancer therapies, attracted new healthcare-focused institutional investors with the offering.
J.P. Morgan and TD Cowen served as lead book-running managers, while Mizuho acted as a book-running manager and A.G.P./Alliance Global Partners and Maxim Group LLC served as lead managers. The offering was conducted under a shelf registration statement filed with the Securities and Exchange Commission on March 20, 2026. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein present in various tumor types.
The company is also developing SLS009, a small molecule CDK9 inhibitor, for the treatment of acute myeloid leukemia in patients with unfavorable prognostic factors.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.